Contrast-enhanced ultrasound may avert prostate biopsies

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies.

A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies. They found generally that contrast ultrasound provided more precise locational information than is available with unenhanced grayscale ultrasound. Biopsies based on the contrast scans resulted in a sensitivity of 85.2%, according to the group from the Medical University of Innsbruck (European Congress of Radiology 2009 abstract C-390).

A group at Shanghai’s Jio Tong University used microflow imaging and found a sensitivity of 80% and an accuracy of 83% for this contrast strategy. However, limitations included cost and training (abstract C-391).

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content